SCHEMBL3515875

SCHEMBL3515875

CCOc1ccc(-c2ccc3ncc4[nH]c(=O)n(-c5cn(CC(=O)N6CCN(C)CC6)nc5C)c4c3c2)cn1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ATM Q13315 12/20 0.43
MTOR P42345 9/20 0.43
PIK3CA P42336 9/20 0.43
ATR Q13535 3/20 0.43
IRAK4 Q9NWZ3 2/20 0.40
PIK3CD O00329 4/20 0.37
PIK3CB P42338 4/20 0.37
KCNH2 Q12809 3/20 0.37
PIK3CG P48736 3/20 0.37
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3513692 0.84 IRAK4 (0.38) IRAK4GRIN1GRIN2B
SCHEMBL3516922 0.83 ATM (0.49) ATMMTORPIK3CAATRPIK3CD
SCHEMBL3515369 0.82 ATM (0.48) ATMMTORPIK3CAATR
SCHEMBL3516760 0.81 ATM (0.49) ATMMTORPIK3CAATRPIK3CD
SCHEMBL3516478 0.77 ATM (0.49) ATMMTORPIK3CAATRPIK3CD
SCHEMBL7876833 0.76 MTOR (0.47) ATMMTORPIK3CAATRPIK3CD
SCHEMBL2068303 0.75 MTOR (0.46) ATMMTORPIK3CAATRPIK3CD
SCHEMBL3515419 0.75 ATM (0.49) ATMMTORPIK3CAIRAK4PIK3CD
SCHEMBL3516892 0.74 ATM (0.48) ATMMTORPIK3CAATRPIK3CD
SCHEMBL3516018 0.73 ATM (0.44) ATMMTORPIK3CAATRIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US claimed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US claimed
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ATM 995/4885MTOR 374/4885PIK3CA 125/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ATM 995/4885MTOR 374/4885PIK3CA 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.